Research work · 2010
Dasatinib
Mônika Conchon, Carla Maria Boquimpani de Moura Freitas, Maria Aparecida do Carmo Rego, José Wilson Ramos Braga
Revista Brasileira de Hematologia e Hemoterapia
Abstract
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.